A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults with Soft Tissue Sarcomas (INVINCIBLE-3)

Recruiting

Phase 3

INT230-6 vs. Standard of CareA Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults with Soft Tissue Sarcomas (INVINCIBLE-3)

Sponsor:

Intensity Therapeutics, Inc.

Code:

NCT06263231

Conditions

Sarcoma,Soft Tissue

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

INT230-6

Eribulin

Trabectedin

Pazopanib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by Intensity Therapeutics, Inc. on 2025-03-25.